Change in fair
value of
derivative asset - - (81) -
Other income
(expense), net (3) 922 12 964
--------- --------- --------- ---------
Loss before
provision for
income taxes (5,732) (4,912) (15,260) (16,934)
Provision for
income taxes - - - -
--------- --------- --------- ---------
Net loss
attributable to
Vaccinex, Inc.
common
stockholders $ (5,732) $ (4,912) $ (15,260) $ (16,934)
========= ========= ========= =========
Comprehensive loss $ (5,732) $ (4,912) $ (15,260) $ (16,934)
========= ========= ========= =========
Net loss per share
attributable to
Vaccinex, Inc.
common
stockholders,
basic and diluted $ (2.83) $ (15.25) $ (8.85) $ (59.95)
========= ========= ========= =========
Weighted-average
shares used in
computing net loss
per share
attributable to
Vaccinex, Inc.
common
stockholders,
basic and diluted 2,026,920 322,153 1,724,088 282,467
========= ========= ========= =========
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/551b0bc4-4495-4a65-aa21-a96daddf079e
(END) Dow Jones Newswires
November 18, 2024 08:30 ET (13:30 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.